X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

DNA2.0 Inc Becomes ATUM

Yuvraj_pawp by Yuvraj_pawp
12th December 2016
in Americas, News

Now combining DNA synthesis, protein expression and protein engineering capabilities, ATUM delivers full suite of service to speed discovery Founded in 2003 to marry computational design and gene synthesis, DNA2.0 was a pioneer in the application of machine learning (or artificial intelligence) to biology.
The company is building on that legacy of invention with a new name: ATUM. In Egyptian mythology, ATUM was the first god, the underlying substance of the world — a product of energy and matter. The new name reflects the company’s expanded focus — manipulating the underlying substance of life (DNA) to engineer biology across the spectrum of scale, from building better genes, proteins and pathways all the way to creation of cells.


“The name ATUM captures the spirit of creation, invention and discovery that typifies who we are,” said Jeremy Minshull, Ph.D., co-founder and CEO. “We are helping to transform biology from a discovery science to an engineering discipline, and seeking out areas where this approach can have the biggest impact. Our vision for this new biology is to help advance solutions for some of the world’s biggest problems — disease, climate change and food insecurity. To do this we are strategically growing our team and introducing new tools. What hasn’t changed is that we do all of this in a very collaborative model, with Ph.D. level scientists who engage with every customer in a peer-to-peer relationship.”


The company’s growth from DNA2.0 to ATUM has evolved with the science, and has been particularly catalyzed by:

  • James Love, Ph.D., joining the company in 2015 to develop and lead protein expression services.
  • The acquisition of MIGS, the antibody engineering powerhouse founded by Michael Feldhaus, Ph.D., who joined the company’s executive team in April 2016.
  • The recent hiring of Ferenc Boldog, Ph.D., who brings decades of pharmaceutical industry experience to establish ATUM’s cell line development offerings.
  • The issuance of the first patents in an emerging LeapIn transposase portfolio. This tool has applications in gene expression, gene therapy and gene discovery, as well as ATUM’s cell line service.


“Historically, we have partnered with companies who use our DNA-based tools in-house,” said Dr. Minshull. “By optimizing the interactions between our molecular tools, cells and growth conditions, we can offer more complete solutions, and speed our partners’ progress. For example, we provide antibody engineering and upstream services to support the search for tomorrow’s drugs, to abate climate change and to solve the problem of food insecurity.”

About ATUM

ATUM, formerly DNA2.0, offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. ATUM exploits the dependence of biological activity on well-designed sequences. ATUM’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. By collaborating with clients, ATUM accelerates breakthroughs and moves research further faster. The company is privately held and is headquartered in Newark, California. For more information, please visit https://www.atum.bio.

 

Contact:
Lisa Lilienthal, 404-661-3679
lisa@iconatl.com

 

Tags: America
Previous Post

Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters into Licensing Agreement with Amryt Pharma for Lojuxta

Next Post

Utilizing QSP Models in Drug Discovery & Development

Related Posts

DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Next Post

Utilizing QSP Models in Drug Discovery & Development

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In